Coronary Heart Disease Risk, Dyslipidemia, and Management in HIV-Infected Persons

REFERENCES

• Bonnet F, Morlat P, Chene G, et al., for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GESCA). Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med. 2002;3:195–199.
   PubMedGoogle Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocar-dial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479–2486.
   PubMed Web of Science ®Google Scholar
• Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endo-thelial function. Endothelium. 2000;7:223–242.
   PubMed Web of Science ®Google Scholar
• Mauss S. HIV-associated and antiretroviral-induced hyperlipidaemia: an update. J HIV Ther. 2003;8:29–31.
   PubMedGoogle Scholar
• Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS. 1997;11:938–939.
   PubMed Web of Science ®Google Scholar
• Henry K, Melroe H, Huebusch J, et al. Severe premature coronary artery disease with protease inhibitors [letter]. Lancet. 1998;351:1328.
   PubMed Web of Science ®Google Scholar
• Vittecoq D, Escaut L, Monsuez JJ. Vascular complica-tions associated with use of HIV protease inhibitors. Lan-cet. 1998;351:1959.
   PubMed Web of Science ®Google Scholar
• Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis [letter]. Clin Infect Dis. 1999;28:161–162.
   PubMed Web of Science ®Google Scholar
• Atte A, Schwenk A, Franzen C, et al. Increasing morbid-ity from myocardial infarction during HIV protease inhibi-tor treatment. [letter] AIDS. 1999;13:1796–1797.
   PubMed Web of Science ®Google Scholar
• Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibi-tors [letter]. Lancet. 1998;351:1958–1959.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Weber R, Reiss P, et al, for the DAD Study Group. Cardiovascular disease risk factors in HIV-in-fected persons-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–1193.
   PubMed Web of Science ®Google Scholar
• Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506–512.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Hariawala MD, Deshmukh W, Sellke FW. Insulin resis-tance: a common factor in the triad of dyslipidemia, hy-pertension, and coronary artery disease? Am J Med Sci. 1997;313: 104–106.
   PubMed Web of Science ®Google Scholar
• Dubé MP, Stein JH, Aberg JA, et al, for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-in-fected adults receiving antiretroviral therapy: recommen-dations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–627
   PubMed Web of Science ®Google Scholar
• Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an Inter-national AIDS Society-USA Panel. J Acquir Immune Defic Syndr. 2002;31:257–275.
   PubMed Web of Science ®Google Scholar
• Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Ser-vices (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. July 14,2003. Available at: http://AIDSinfo.nih.gov. Accessed August 23, 2003.
   Google Scholar
• Hulley SB. The US National Cholesterol Education Pro-gram. Adult treatment guidelines. Drugs. 1988;36\(suppl 3):100–104.
   PubMed Web of Science ®Google Scholar
• Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835–2838.
   PubMed Web of Science ®Google Scholar
• Assmann G. Pro and con: high-density lipoprotein, trig-lycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol. 2001;87(suppl 5A):2B–7B.
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H. Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovas-cular Munster Study. Am J Cardiol. 1992;70:10H–13H.
   Google Scholar
• Simons LA, Simons J, Friedlander Y, McCallum J. Cho-lesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis. 2001;159:201–208.
   PubMed Web of Science ®Google Scholar
• Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immu-nodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993;76:1423–1427.
   PubMed Web of Science ®Google Scholar
• Shor-Posner G, Basit A, Lu Y, et al. Hypercholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med. 1993; 94:515–519.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289: 2978–2982.
   PubMed Web of Science ®Google Scholar
• Barbarini G, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS. 2003;17\(suppl 1):546–50.
   Google Scholar
• Barbaro G. Pathogenesis of HIV-associated heart dis-ease. AIDS. 2003;17\(suppl 1):512–20.
   Google Scholar
• Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothe-lial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coil Cardiol. 2003;42:1037–1043.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Nam BH, D'Agostino RB, et al. Carotid intima-media thickness is associated with premature parental coronary heart disease: the Framingham Heart Study. Circulation. 2003;108:572–576.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Com-parison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002347: 1557–1565.
   Google Scholar
• Ridker PM. High-sensitivity C-reactive protein and car-diovascular risk: rationale for screening and primary pre-vention. Am J Cardiol. 2003;92:17K–22K.
   Google Scholar
• Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coro-nary atherosclerosis and arteriosclerosis in young hu-man-immunodeficiency-virus-positive patients. Coronary Artery Dis. 2000;11:41–46.
   PubMed Web of Science ®Google Scholar
• Acevedo M, Sprecher DL, Calabrese L, et al. Pilot study of coronary atherosclerotic risk and plaque burden in HIV-infected persons: "a call for cardiovascular preven-tion." Atherosclerosis. 2002;163:349–354.
   PubMed Web of Science ®Google Scholar
• Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol. 1993;144:225–231.
   PubMedGoogle Scholar
• Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr. 1994;7:1149–1156.
   PubMed Web of Science ®Google Scholar
• Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 pa-tients. Eur J Clin Invest. 1994;24:416–420.
   PubMed Web of Science ®Google Scholar
• David MH, Hornung R, Fichtenbaum CJ. Ischemic car-diovascular disease in persons with human immunodefi-ciency virus infection. Clin Infect Dis. 2002;34:98–102.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115–126.
   PubMed Web of Science ®Google Scholar
• Henry K, Zackin R, Dube M, Hammer S, Sprecher D, Currier J, for the ACTG 50561372A Team. ACTG 5056: C-reactive protein (CRP) levels and cardiovascular risk sta-tus for a cohort of HIV-1 infected persons durably sup-pressed on an indinavir (IDV)-containing regimen. In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, Washington. Abstract 694–T.
   Google Scholar
• Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?J Acquir Immune Defic Syndr. 2002;30:471–477.
   Google Scholar
• Hsue PY, Kamini G, Erickson S, et al. Clinical features of acute coronary syndromes in patients with human immu-nodeficiency virus infection. Circulation. 2004;109:316–319.
   PubMed Web of Science ®Google Scholar
• Varriale P, Saravi G, Hernandez E, Carbon F. Acute myo-cardial infarction in patients with human immunodefi-ciency virus. Am Heart J. 2004;147:55–59.
   PubMed Web of Science ®Google Scholar
• Holmberg SD, Moorman AC, Williamson JM, et al, HIV Outpatient Study (HOPS) Investigators. Protease inhibi-tors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747–1748.
   PubMed Web of Science ®Google Scholar
• Law M, Friis-Moller N, Weber R, et al, for the DAD Study Group. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med. 2003;4:1–10.
   PubMedGoogle Scholar
• Law M, D'Arminio Monforte A, Friis-Moller N, et al. Cardio- and cerebrovascular events (CVE) and predicted rates of myocardial infarction (MI) in the DAD study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, California. Poster 737.
   Google Scholar
• Rickerts V, Brodt H-R, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients be-tween 1983 and 1998: the Frankfurt HIV-Cohort Study. Eur J Med Res. 2000;5:329–333.
   PubMedGoogle Scholar
• Iloeje U, Yuan Y, L'Italien G et al. Protease inhibitor (Pis) exposure time and risk of cardiovascular disease (CHD) in human immunodeficiency virus (HIV) infected patients. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, California. Poster 736.
   Google Scholar
• Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702–710.
   PubMed Web of Science ®Google Scholar
• Klein D, Hurley L, Queensbury C, et al. Hospitalization for coronary heart disease and myocardial infarction among men with HIV-1 infection: follow-up through 12/31/03. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, California. Poster 739.
   Google Scholar
• Jacoby DS, Mohler III ER, Rader DJ. Noninvasive athero-sclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. Curr Atheroscler Rep. 2004;6:20–26.
   PubMedGoogle Scholar
• Currier J, Kendall M, Henry K, et al. Carotid intima-media thickness in HIV-infected and uninfected adults: ACTG 5078. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, Massachusetts. Abstract 131.
   Google Scholar
• Hsue P, Lo J, Franklin A, Bolger AF, Deeks SG, Waters DD. Increased atherosclerotic progression in patients with HIV: the role of traditional and immunological risk factors. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, Massachusetts. Abstract 1391b.
   Google Scholar
• Meng Q, Lima JAC, Lai H, et al. Coronary artery calcifica-tion, atherogenic lipid changes, and increased erythro-cyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J. 2002144: 642–648.
   Google Scholar
• Talwani R, Falusi OM, Mendes de Leon CF, et al. Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30:191–195.
   PubMed Web of Science ®Google Scholar
• Torre D, Pugliese A, Orofino G. Effect of highly active antiretroviral therapy on ischemic cardiovascular disease in patients with HIV-1 infection. Clin Infect Dis. 2002;35:631–632.
   PubMed Web of Science ®Google Scholar
• Levy AR, Iloeje U, Hogg RS, et al. Increases in blood cholesterol and triglycerides among persons with HIV/ AIDS on highly active antiretroviral therapy compared with population norms. Antivir Ther. 2003;8:L48. Abstract 66.
   Web of Science ®Google Scholar
• Danner SA, Carr A, Leonard JM, et al, for the European-Australian Collaborative Ritonavir Study Group. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995;333:1528–1533.
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal sub-jects. AIDS. 2000;14:51–57.
   PubMed Web of Science ®Google Scholar
• Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with pro-tease inhibitors. Circulation. 1999;100:700–705.
   PubMed Web of Science ®Google Scholar
• Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 200115: 1–9.
   Google Scholar
• Dubé MP, Qian D, Edmondson-Melançon H, et al. Pro-spective, intensive study of metabolic changes associ-ated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002;35:475–481.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Bernstein B, King M, et al, for the M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039–2046.
   PubMed Web of Science ®Google Scholar
• Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL choles-terol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274:1771–1774.
   PubMed Web of Science ®Google Scholar
• Koppel K, Bratt G, Eriksson M, Sandstrom E. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS. 2000;11:451–455.
   PubMed Web of Science ®Google Scholar
• Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associ-ated with atherogenic lipoprotein changes and endothe-lial dysfunction. Circulation. 2001104: 257–262.
   Google Scholar
• Fisac C, Fumero E, Crespo M, et al. Metabolic changes in patients switching from a protease inhibitor-containing regimen to abacavir, efavirenz or nevirapine: 24 month results of a randomized study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunis-tic Infections; 2004; San Francisco, California. Abstract 78.
   Google Scholar
• Markowitz M, Simon V, Vasan S, et al. 48-week results of an atazanavir-based QD regimen in patients switching from BID-based HAART. Antivir Ther. 2003;8\(suppl 1):5329. Abstract 543.
   Google Scholar
• Murphy R, Pokrovsky V, Rozenbaum W, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS study 008/044. In: Pro-gram and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, Massachusetts. Abstract 555.
   Google Scholar
• Sanne 1, Piliero P, Squires K, Thiry A, Schnittman S, for the A1424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (A1424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Im-mune Defic Syndr. 2003;32:18–29.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Grunfeld C, Tal VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors inde-pendent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35–43.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated Ii-podystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–2099.
   PubMed Web of Science ®Google Scholar
• Bruno R, Gazzaruso C, Sacchi P, et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk [letter]. J Acquir Immune Defic Syndr. 2002;31:363–365.
   PubMed Web of Science ®Google Scholar
• Walli R, Herfort O, Michl GM, et al. Treatment with pro-tease inhibitors associated with peripheral insulin resis-tance and impaired oral glucose tolerance in HIV-1-in-fected patients. AIDS. 1998;12:F167–F173.
   PubMed Web of Science ®Google Scholar
• Haffner SM. Pre-diabetes, insulin resistance, inflamma-tion and CHD risk. Diabetes Res Clin Pract. 2003;61\(suppl 1):S9–S18.
   PubMed Web of Science ®Google Scholar
• Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 200115: 11–18.
   Google Scholar
• Dube M, Zackin R, Parker R, et al, Prospective study of glucose and lipid metabolism in antiretroviral naive sub-jects randomized to receive nelfinavir, efavirenz or both combined with zidovudine + lamivudine (ZDV+3TC) or didanosine + stavudine: A5005s, a substudy of ACTG 384. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Fran-cisco, California. Abstract 74.
   Google Scholar
• Sension M, Thiry A, Giordano M, for the A1424-034 Inter-national Study Team. Absence of insulin resistance through week 24 with atazanavir once-daily and efavirenz once-daily each with fixed-dose zidovudine plus lamivudine. Antivir Ther. 2002;7:L26. Abstract 36
   Web of Science ®Google Scholar
• Mascolini M. On the trail of fugitive fat: the chase turns to NRTIs. J Int Assoc Physicians AIDS Care 1999;5:24–43.
   PubMedGoogle Scholar
• Vigouroux C, Gharakhanian S, Salhi Y, et al. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. 1999;25:383–392.
   PubMed Web of Science ®Google Scholar
• Lewis W. Mitochondrial DNA replication, nucleoside re-verse-transcriptase inhibitors, and AIDS cardiomyopathy. Prog Cardiovasc Dis. 2003;45:305–318.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Gallant JE, Pozniak AL, et al, for the 903 Study Team. Efficacy and safety of tenofovir DF vs stavudine when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week prelimi-nary interim results. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infec-tions; February 10–14, 2003; Boston, Massachusetts. Poster 564b.
   Google Scholar
• Kumar P, Rodriguez-French A, Thompson M, et al. Pro-spective study of hyperlipidemia in ART-naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002). In: Program and abstracts of the Ninth Con-ference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, Washington. Abstract 33.
   Google Scholar
• Fontas E, Van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination therapy: Are dif-ferent antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056–1074.
   Google Scholar
• van der Valk M, Kastelein JJP, Murphy RL, et al, for the Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407–2414.
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Katlama C, Murphy RL, et al. A random-ized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17:987–999.
   PubMed Web of Science ®Google Scholar
• Simon GL, Liappis AP, Granger SL, et al. Antiretroviral therapy-induced changes in lipoprotein subclass pheno-type: comparison of protease inhibitor and non-nucleoside reverse transcriptase inhibitor regimens. Antivir Ther. 2002;7:L9. Abstract 14.
   Web of Science ®Google Scholar
• Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Tri-als. 2003;4:29–36.
   PubMed Web of Science ®Google Scholar
• van Leth F, Hassink E, Phanuphak P, et al, for the 2NN Study Group. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, with stavudine and lamivudine. In: Program and abstracts of the 10th Confer-ence on Retroviruses and Opportunistic Infections; Feb-ruary 10–14, 2003; Boston, Massachusetts. Abstract 176.
   Google Scholar
• van Leth F, Phanuphak P, Gazzard B, et al, for the 2NN Study Group. Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens con-taining either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN study). In: Program and abstracts of the 10th Con-ference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, Massachusetts. Abstract 752.
   Google Scholar
• Shahmahesh M, das S, Stolinski M, et al. Insulin resis-tance and apolipoprotein B kinetics: a comparison of protease inhibitor, efavirenz, or nevirapine-containing antiretroviral regimens. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic In-fections; 2004; San Francisco, California. Poster 704.
   Google Scholar
• Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002;35:1219–1230.
   PubMed Web of Science ®Google Scholar
• Negredo E, Ribalta J, Paredes R, et al. Reversal of athero-genic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383–1389.
   PubMed Web of Science ®Google Scholar
• Gil P, Górgolas M, Estrada V, et al. Efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected persons with undetectable viral load: results after 3 years. In: Program and abstracts of the Second International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13–16, 2003; Paris, France. Abstract 590.
   Google Scholar
• Martinez E, Arnaiz JA, Podzamczer D, et al, for the Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for pro-tease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036–1046.
   PubMed Web of Science ®Google Scholar
• Fisac C, Fumero E, Crespo M, et al. Metabolic and body composition changes in patients switching from a P1-containing regimen to Abacavir, Efavirenz or Nevirapine. 12 month results of a randomized study (LIPNEFA). In: Program and abstracts of the XIV International AIDS Con-ference; July 7–12, 2002; Barcelona, Spain. Abstract ThPE7354.
   Google Scholar
• Martinez E, Podzamczer E, Ribera P, et al. Switching protease inhibitors to nevirapine, efavirenz or abacavir: a randomized, multicenter, open-label, simplification trial. In: Program and abstracts of the XIV International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Abstract WeOrB1262.
   Google Scholar
• Fichtenbaum CJ. The evaluation and management of dyslipidemia in HIV-infected patients. AIDS Clin Care. 2001;13:113-117, 120.
   Google Scholar
• Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolemia associated with protease inhibitor therapy. AIDS. 2001;15:1503–1508.
   PubMed Web of Science ®Google Scholar
• Stein JH, Wu Y, Kawabata H, Iloeje UH. Increased use of lipid-lowering therapy in patients receiving human immu-nodeficiency virus protease inhibitors. Am J Cardiol. 2003;92:270–274.
   PubMed Web of Science ®Google Scholar
• Stein EA The power of statins: aggressive lipid lowering. Clin Cardiol. 2003;26(4 suppl 3)11125–11131.
   Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al., NIAID AIDS Clinical Trials Group. Pharmacokinetic inter-actions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS. 2002;16:569–577.
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Lewis RH, Schultz MD, Lillibridge JH, Kerr BM. Pharmacokinetic interactions between nelfinavir and two HMG-CoA reductase inhibitors simvastatin and atorvastatin. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto, Ontario, Canada. Abstract 425.
   Google Scholar
• Schuster H. Rosuvastatin-a highly effective new 3-hy-droxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology. 2003;99:126–139.
   PubMed Web of Science ®Google Scholar
• Carr RA, Andre AK, Bertz RJ, Hsu A, Lam W, Chang M. Concomitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokinetic (PK) interaction with atorvastatin (ATO) but not pravastatin. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto, Ontario, Canada. Abstract 1644.
   Google Scholar
• Gerber JG, Fichtenbaum CJ, Rosenkranz S, et al. Efavirenz (EFV) is a significant inducer of simvastatin (SIM) and atorvastatin (ATR) metabolism: results of ACTG A5108 study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004; San Francisco, California. Abstract L–3.
   Google Scholar
• Narayan S, Hawley N, Giguère P, Badley AD. Attenuated T-lymphocyte response to HIV therapy in individuals re-ceiving HMG-CoA reductase inhibitors. HIV Clin Tri-als. 2003;4:164–169.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Zackin RA, Evans SR, et al., and ACTG 5087 Team. A prospective, multicenter, randomized trial com-paring the efficacy and safety of fenofibrate (F) versus pravastatin (P) in HIV-infected subjects with lipid abnor-malities: final results of ACTG 5087. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004; San Fran-cisco, California. Abstract N–53.
   Google Scholar
• Calza L, Manfredi R, Chiodo F. Dyslipidemia associated with antiretroviral therapy in HIV-infected patients. J Anti-microbial Chemother. 2004;53:10–14.
   PubMed Web of Science ®Google Scholar
• Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-re-lated lipid abnormalities. Lancet. 1998;352:1031–1032.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Calza L, Chiodo F. Statins and fibrates for the treatment of hyperlipidemia in HIV-infected patients re-ceiving HAART. AIDS. 2003:17:851–859.
   PubMed Web of Science ®Google Scholar
• Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS. 1999;13:868–869.
   PubMed Web of Science ®Google Scholar
• Caramelli B, de Bernoche CY, Sartori AM, et al. Hyperlipi-demia related to the use of HIV-protease inhibitors: natu-ral history and results of treatment with fenofibrate. Braz J Infect Dis. 2001;5:332–338.
   PubMedGoogle Scholar
• Kahn SE, Beard JC, Schwartz MW, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989;38:562–568.
   PubMed Web of Science ®Google Scholar